Format

Send to

Choose Destination
See comment in PubMed Commons below
Nihon Hansenbyo Gakkai Zasshi. 2013 Dec;82(3):143-84.

[Guidelines for the treatment of Hansen's disease in Japan (third edition)].

[Article in Japanese]

Author information

1
National Sanatorium Hoshizuka-Keiaien. masagoto@hoshizuka.hosp.go.jp
2
National Kikuchi Keifuen Sanatorium.
3
National Sanatorium Oku-Komyoen.
4
National Hansen's Disease Museum.
5
National Center for Global Health and Medicine.
6
Amakusa City Ushibuka Hospital.
7
Department of Pathology, Kagoshima University Hospital.
8
Leprosy Research Center, National Institute of Infectious Diseases.
9
Department of Dermatology, Kyoto University.

Abstract

ad hoc committee of Japanese Leprosy Association recommends revised standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 2010). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) > 3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. When BI becomes negative and active lesion is lost within 2 years, no maintenance therapy is necessary. When BI is still positive, one year of MDT/MB is added (3 years in total), followed by maintenance therapy by dapsone and clofazimine until BI negativity and loss of active lesions. (B) For MB with BI < 3 or fresh MB (less than 6 months after the onset of the disease) with BI > 3, 1 year treatment by MDT/MB is necessary. When BI becomes negative and active lesion is lost within one year, no maintenance therapy is necessary. When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.

PMID:
24579462
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center